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Osteoporosis and fragility fractures (FF) are associated with corticosteroids which are the 
mainstay treatment for asthma; however, these bone comorbidities within asthma need to be 
better described. 
Methods  
A matched cohort study was conducted using the Clinical Practice Research Database 
(CPRD). Adults with an incident asthma code were identified and matched, with up to four 
randomly selected people without asthma, by age, gender, and practice. Osteoporosis and FF 
incidence rates were calculated, and Cox regression was performed comparing hazard rates 
to the general population. We report the impact of age, gender, glucocorticoids, and the risk 
of specific fractures.  
Results 
Patients with asthma had a higher risk of osteoporosis (aHR = 1.18, 95% CI: 1.13-1.23) and 
were 12% (aHR = 1.12, 95% CI: 1.07-1.16) more likely to sustain FF than the general 
population. Age modified the effect of asthma on osteoporosis and FF, such that effect to be 
stronger in younger people (pinteraction<.0001). Vertebral (aHR = 1.40, 95% CI: 1.33-1.48), and 
forearm-wrist (aHR = 1.27, 95% CI: 1.22-1.32) were the sites linked with a larger incidence. A 
dose-response relationship between oral corticosteroids (OCS) and osteoporosis was 
observed, whereas the risk of FF increased in those with 6 or more OCS courses per year. 
Regular use of inhaled corticosteroids (ICS) increased the risk of both bone conditions. 
Conclusion 
Patients with asthma are more likely to develop osteoporosis or sustain FF than the general 







Asthma is a common chronic inflammatory disease affecting 300 million people of all ages (1). 
ICS are considered the gold-standard treatment, with OCS to be used in people with difficult 
asthma, or for exacerbations (2). Asthma is amongst the most common indications for 
prolonged (≥ 3 months) OCS therapy (3). Additionally, 17% of people with asthma have 
difficult-to-treat asthma (4) and 30%  of them receive up to the equivalent of 20mg 
prednisolone equivalent and almost half of them receive up to over 2000 μg of ICS per day 
(5). Although corticosteroids are the main asthma treatment, there are well-recognised 
deleterious effects (6–9). 
Osteoporosis which can result in FF is the most common severe and preventable side effect 
of steroid use (10). FF are associated with substantially increased health care costs, morbidity, 
and mortality (11,12). In a general population, studies suggest an increased fragility fracture 
risk in patients exposed to both short (≤ 3 months) and prolonged OCS use (8,13). Vertebral 
fracture risk increases by 55% with exposure at doses as low as prednisone 2.5mg per day, 
whereas hip fracture risk increases by 77% in patients exposed to 2.5 - 7.5mg per day (13). 
ICS also carry risk; compared to controls, people with an airway disease exposed to ICS have 
a higher fracture risk ranging from 15% to 51% depending on the fracture location (14). 
Although there is a clear link between OCS and ICS use, and the risk of osteoporosis and FF, 
less is known about the relationship between asthma and these bone diseases. Some studies 
have examined this relationship, but they have used as outcome any change in the bone 
mineral density (BMD) with conflicting findings (15–19). Patients with severe asthma exposed 
to 5mg of prednisolone per day are more likely to be diagnosed with osteoporosis (OR=6.53) 
and fracture (OR=1.65) compared to those without asthma (20). A high prevalence of fractures 
in patients with steroid dependent asthma has been also reported (21,22). However, 




The aim of this study was to estimate the incidence and risk of osteoporosis and FF among 
patients with asthma, when compared to the general population. We reported the impact of 






We conducted a matched cohort study utilising the Clinical Practice Research Datalink, a large 
longitudinal primary care database. We used the July 2018 dataset which covers more than 
15.4 million patients from 738 practices across the UK. The percentage of acceptable active 
patients is approximately 7% of the UK population and data are representative with respect to 
age, gender and ethnicity to the wider UK people (23). The study was approved by the 
Independent Scientific Advisory Group of the CPRD (ISAC protocol number 19_041RA). 
Study population 
The study population included all adults patients (≥18 years old) with a new Read code for 
asthma between 1st April 2004 (activation of Quality and Outcomes Framework score) to 31th 
December 2017, with at least 1 year of data collection prior to the index date (24). We assigned 
an index date equal to a new Read code for asthma to each patient with asthma. Each patient 
with asthma was matched up to four randomly selected patients without asthma (not any 
record of Read code for asthma) by age (±1 year), gender and practice generating a matched 
cohort. We assigned to patients without asthma the same index date as their matched 
patients. Only patients classed as “acceptable” research quality data and registered to an up 
to standard practice according to CPRD’s recommendations included. 
Definition of outcomes 
The outcomes of interest were the time from the index date to the first Read code for 1) 
osteoporosis and 2) FF, separately. Patients with a previous history of osteoporosis and the 
specific fracture outcome under investigation before the index date were excluded. The FF 
were defined as composite of vertebral, hip, forearm-wrist and humerus fractures. An 
additional category called “unspecified” was generated including fractures classified as FF 
without specifying the exact fracture location. We selected these locations as they are 




fracture described as an “open fracture” was excluded, since this type usually occurs via a 
high-energy event, and is not associated with frailty.  
Follow-up 
The index date was the start date of the follow-up and the end date was defined as the date 
of the patient’s death, the date of the last collection of the practice, the date of the patient 
transferred out of the practice, the date of the first Read coded outcome of interest or the end 
of the dataset, whichever came earliest.  
Potential confounders 
For each participant in this study, we retrieved information on the following variables, all of 
which are well-established risk fractures or thought to have an impact on osteoporosis or 
fracture risk and are also likely to be recorded within the database: age at the index date; sex, 
including only those clearly classified as male or female; body mass index (BMI) using the 
nearest measurement prior to the index date and categorised according to the World Health 
Organization (supplementary material); smoking and alcohol status using the nearest 
measurement prior to the index date (supplementary material); socioeconomic status 
measured by using the patient-level Index of Multiple Deprivation (IMD) 2015 in quintiles (with 
quintile 1 being the least deprived and quintile 5 being the most deprived; history of any 
fracture (not those considered as an outcome), fall or chronic obstructive pulmonary disease 
(COPD) prior to the index date; at least one prescription of opioids, vitamin D and calcium, 
and hormone replacement therapy (HRT) in the year prior to the index date. The comorbidities 
were also summarised using the Charlson Comorbidity Index score (26). 
Exposure to OCS, ICS and bisphosphonates was calculated in two ways. We calculated their 
use in the year before the index date. Then, the OCS and ICS prescription rates per patient 
per year of follow-up were also estimated by dividing the total number of prescriptions of each 
patient during the follow-up period to the corresponding person- time of each one patient 




one bisphosphonate prescription after OCS initiation was calculated. If there was no record 
for a medication or diagnosis, we assumed that the patient did not have the exposure.  
Statistical analysis 
All continuous demographic and lifestyle variables were summarised using mean and 
standard or median and interquartile range for those following normal or skewed distribution, 
respectively. Categorical variables were summarised by frequency and percentages. We 
compared the baseline characteristics between asthma and non-asthma patients performing 
a conditional logistic regression analysis using the matched set as the strata variable. Absolute 
incidence rates of osteoporosis and FF were calculated by dividing the number of incident 
diagnosis by follow-up person-years for both groups. The probability of experiencing FF during 
the follow-up time was presented with a plot using the Kaplan-Meier method and the log-rank 
test examined any difference between the groups. Performing a Cox regression analysis, 
stratified by matched set, we calculated the hazard ratio (HR) estimates and 95% confidence 
intervals (CI) comparing the osteoporosis and FF risk between asthma and non-asthma 
patients. Then, we adjusted our model for a priori confounders (age and gender) and the other 
potential confounders listed above. These confounders were included in the model whether 
they altered the age-gender adjusted HR between exposure and outcome by 5% or more. The 
Cox model assumption was tested using Schoenfeld residuals. Missing data for BMI, smoking 
status, and alcohol status were assumed as missing at random and imputed using chained 
equations. Ten imputations were generated, and the imputed model consisted of age, gender, 
outcome, and all confounders. Missing data for IMD were assigned a new category. A 
subgroup analysis by gender, age group, and fracture location was performed. To test whether 
or not age or gender modified the effect of asthma on osteoporosis and FF, we used the 
likelihood ratio test to examine for statistical evidence of effect modification. 
To test the robustness of our findings, we also conducted two sensitivity analyses to determine 




the main analysis (a) including patients with a history of osteoporosis before the index date, 
and (b) excluding patients with any fracture before the index date. 
After excluding the patients without asthma, we investigated the effect on osteoporosis and 
FF of some well-known risk factors within asthma group, including ICS and OCS prescriptions 
during the follow-up, by estimating aHR.  








The study included 138,123 patients with asthma and 520,626 age-, sex- and practice- 
matched non-asthma patients. The mean age of people with and without asthma was 
52.0±17.9 and 51.7±17.8, respectively (Table 1). The median follow-up time was 4.50 (IQR: 
2.1-7.9) in asthma and 4.58 (IQR: 2.1-8.0) in non-asthma patients.  
Patients with asthma compared to non-asthma were more likely to be obese (27% vs 17%, 
p<.0001) and ex- or current smokers (53% vs 40%, p<.0001) (Table 1). Furthermore, patients 
had had more comorbidities than controls (p<.0001). More patients with asthma had at least 






Table 1. Baseline characteristics of asthma and non-asthma patients. 
 Asthma patients Nonasthma patients  
Descriptor n=138,123 %* n=520,626 %* p-value** 
Age y, mean ± SD 52.0±17.9  51.7±17.8   
             <40 39,043 28.3 149,685 28.7  
40-49 24,998 18.1   95,308 18.3  
50-59 23,974 17.4   90,549 17.4  
60-69 24,774 17.9   92,478 17.8  
70-79 17,417 12.6   64,307 12.3  
≥80   7,917   5.7   28,299   5.4  
Gender      
Male 56,538 40.9 213,635 41.0  
Female 82,585 59.1 306,991 59.0  
Follow-up y, median (IQR)a 4.50 (2.1-7.9) 4.58 (2.1-8.0)  
Follow-up y, median (IQR)b 4.51 (2.1-7.9) 4.60 (2.1-8.0)  
IMD     <.0001 
Least Deprived 16,026               11.6   62,026            11.9  
- 16,439              11.9   61,102             11.7  
- 16,030               11.6   58,013             11.1  
- 15,341              11.1   52,752             10.1  
Most deprived 14,612               10.5   46,284                 8.8  
Missing status 59,675               43.2 240,339             46.1  
CCI score      <.0001 
1 113,950 82.5 447,602 86.0  
2 11,796   8.5   38,310   7.4  
3   6,452   4.7   18,572   3.6  
4   2,855   2.1     7,790   1.5  
           ≥5   3,070   2.2     8,352   1.6  
BMI (kg/𝐦𝟐)     <.0001 
Underweight (<18.5)   2,214   1.6     6,676   1.3  
Normal (18.5 - 24.9) 31,486 22.8 111,417 21.4   
Overweight (25 - 29.9) 37,110 26.9 109,519 21.0  
Obese (≥30) 36,890 26.7   86,361 16.6  
Missing status 30,423 22.0 206,653 39.7  
Smoking status     <.0001 
Never  62,095 45.0 254,418 48.9  
Former  42,307 30.6 103,230 19.8  
Current  30,760 22.3 103,729 19.9  
Missing status   2,961   2.1   59,249 11.4  
Alcohol consumption     <.0001 
Never 13,759 10.0   46,968   9.1  
Former 11,734   8.5   33,039   6.3  
Occasional  18,102 13.1   60,005 11.5  
Current  74,419 53.9 261,961 50.3  
Missing status 20,109 14.6 118,653 22.8  
At least one prescription of 
Bisphosphonates    3,923   2.8   11,628   2.2 <.0001 
Opioids 14,321 10.4   31,781   6.1 <.0001 
Vitamin D and/or 
Calcium intake  
  4,386   3.2   12,308   2.4 <.0001 
HRT 11,237   8.1   34,460   6.6 <.0001 
ICS  70,024 50.7    23,136   4.4   <.0001 
OCS  34,221 24.8    18,799  3.6 <.0001 
History of     
Falls  11,758   8.5   33,169   6.4 <.0001 
Any fracture 29,139 21.1   95,523 18.3 <.0001 
COPD 15,365 11.1   11,345   2.2 <.0001 
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; HRT, 
hormone replacement therapy; ICS, inhaled corticosteroids; IMD, Index of Multiple Deprivation; OCS, oral corticosteroids. 




b The outcome was an osteoporosis diagnosis 
*Percentages have been rounded and might not total 100. 







During the whole study period the incidence of osteoporosis was higher in asthma than non-
asthma group. The incidence rates were 5.26 (95% CI: 5.09-5.42) and 3.23 (95% CI: 3.16-
3.29) per 1000 person-years for patients with and without asthma, respectively (Table 2). An 
association between asthma and osteoporosis was observed (aHR = 1.18, 95% CI: 1.13-
1.23). Age and gender modified the effect of asthma on osteoporosis, such that effect to be 
stronger in younger people (pinteraction<.0001) and slightly larger in men with asthma 
(pinteraction<.0001), respectively. The risk stratified by age groups and gender is presented in 






Table 2. Incidence rates and hazard ratios (HR) for associations of osteoporosis with exposure to asthma. 
Variables 
Asthma patients Non-asthma patients 
Unadjusted 
HR (95%CI) 









Rate per 1000 
person-years 
   
Overall 3,767   5.26 9,911 3.23 1.45 (1.40-1.51) 1.18 (1.13-1.23) <.0001 
Gender        
Male    768   2.60 1,431 1.27 2.05 (1.88-2.24) 1.35 (1.22-1.50) <.0001 
Female 2,999   7.11 8,480 4.37  1.35 (1.29-1.41) 1.14 (1.09-1.20) <.0001 
Agea        
<40      55   0.28    126 0.17 1.67 (1.22-2.30) 1.54 (1.04-2.29)   .032 
40-49    208   1.48    496 0.93 1.59 (1.35-1.87) 1.29 (1.06-1.57)   .013 
50-59    678   5.06 1,697 3.01  1.51 (1.38-1.65) 1.24 (1.12-1.39) <.0001 
60-69 1,195   8.97 3,049 6.02 1.49 (1.39-1.59) 1.20 (1.10-1.29) <.0001 
70-79 1,182 15.04 3,269 6.19 1.42 (1.33-1.52 1.17 (1.08-1.26) <.0001 
≥80    449 15.99 1,274 5.81 1.36 (1.22-1.52) 1.16 (1.02-1.32)   .022 
a  Age at the index date. 






Osteoporosis risk among patients with asthma 
Increasing OCS prescriptions raised the risk with patients exposed to nine or more 
prescriptions per year of follow-up to be at higher risk than non-exposed (aHR = 6.11, 95% CI 
5.31-7.02) (Table 3). Nevertheless, only 55% of patients exposed to nine or more OCS 
courses had at least one BP prescription after OCS initiation during the follow-up 
(Supplementary Table E2). Risk of osteoporosis increased with regular use of ICS prescription 
per year, however a substantial increase was observed after the 17th prescription per year of 





Table 3. Risk of osteoporosis within asthma patient stratified by well-known risk factors. 










OCS prescriptions per person-year (n)    <.0001 
0        (120,761) 2,341   3.67   Reference   Reference  
1-2     (8,489)    434   9.29   2.57 (2.31-2.86)   1.75 (1.57-1.95)  
3-5     (5,797)    463 15.79   4.41 (3.97-4.89)    2.49 (2.24-2.77)  
6-8     (1,652)    234 28.33   7.91 (6.92-9.18)   3.82 (3.28-4.44)  
≥9      (1,424)    295 54.03 15.36 (13.48-17.50)   6.11 (5.31-7.02)  
ICS prescriptions per person-year (n)    <.0001 
0        (50,199) 1,234   4.87   Reference   Reference  
1-8     (79,430) 1,663   3.72   0.76 (0.70-0.81)   0.98 (0.92-1.05)  
9-13   (7,068)    429 11.51   2.51 (2.22-2.85)   1.72 (1.52-1.94)  
14-16 (980)    254 41.41   9.94 (7.99-12.35)   5.48 (4.41-6.82)  
≥17    (446)    187 79.11 16.24 (12.70-18.12) 10.66 (8.20-12.05)  
Gender     <.0001 
Male    768   2.61   Reference   Reference  
Female 2,999   7.11   2.73 (2.52-2.95)   3.03 (2.80-3.28)  
Age     <.0001 
≤40      55   0.28   Reference   Reference  
40-49    208   1.48   5.29 (3.93-7.13)   5.43 (4.03-7.32)  
50-59    678   5.05 18.06 (13.72-23.78) 18.00 (13.66-23.73)  
60-69 1,195   8.97 32.31 (24.65-42.34) 31.27 (23.79-41.10)  
70-79 1,182 14.12 51.71 (39.46-67.76) 45.34 (34.43-59.72)  
≥80    449 15.99 60.66 (45.83-80.29) 47.13 (35.36-62.79)  
Smoking     <.0001 
Never 1,435   4.37   Reference   Reference  
Former 1,381   6.39   1.10 (1.01-1.20)   1.14 (1.06-1.24)  
Current    949   5.79   1.40 (1.27-1.55)   1.46 (1.34-1.59)  
BMI (kg/𝒎𝟐)     <.0001 
Underweight (<18.5)    253 14.18   1.48 (1.23-1.87)   1.50 (1.25-1.80)  




Overweight (25 - 29.9) 1,195   4.83   0.67 (0.62-0.73)   0.68 (0.63-0.74)  
Obese (≥30)    880   3.21   0.49 (0.44-0.53)   0.50 (0.46-0.55)  
IMD      <.0001 
Least deprived    381   4.61   Reference   Reference  
-    401   4.96   1.08 (0.94-1.25)   1.01 (0.87-1.15)  
-    381   4.84   1.06 (0.92-1.22)   0.99 (0.86-1.14)  
-    370   4.95   1.08 (0.93-1.25)   1.02 (0.88-1.17)  
Most deprived    429   6.17    1.35 (1.17-1.55)   1.36 (1.18-1.56)  
Not known IMD 1,805   5.47   1.18 (1.05-1.31)   1.21 (1.08-1.35)  
           Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ICS, Inhaled Corticosteroids; IMD, Index of Multiple Deprivation; OCS, Oral corticosteroids 
           a Adjusted for age, gender, smoking, BMI, Charlson score, ICS, OCS, IMD, previous: COPD, fractures. 
 
                 
 




Fragility fracture risk 
A total of 4286 (3.1%) patients with asthma and 13040 (2.5%) without asthma sustained a FF. 
The incidence rates were 5.99 (95% CI 5.81-6.17) in asthma and 4.77 (95% CI 4.69-4.85) in 
non-asthma group per 1000 person-years (Table 4). After adjusting for confounders, the FF 
risk was 12% higher in patients with asthma than those without asthma (aHR = 1.12, 95% CI 
1.07-1.16). The Kaplan-Meier graph also displayed a significantly higher probability of fracture 
during the follow-up between the patients with and without asthma (Log-rank test, p < .0001) 
(Supplementary Figure E1). The effect of asthma on FF risk was modified by age 
(pinteraction<.0001), but not gender (pinteraction=.9972). The risk stratified by age groups and 
gender is presented in the Supplementary Table E3. Forearm-wrist (aHR = 1.21, 95% CI 1.13-
1.30) and vertebral (aHR = 1.19, 95% CI 1.10-1.28) were the sites with a higher risk (Table 
5). The risk of site-specific FF stratified by gender and age groups is summarised in 






Table 4. Incidence rates and hazard ratios (HR) for associations of fracture with exposure to asthma. 
Variables 
Asthma patients Non-asthma patients 
Unadjusted 
HR (95%CI) 









Rate per 1000 
person-years 
   
Overall 4,286   5.99 13,040   4.77  1.26 (1.21-1.30) 1.12 (1.07-1.16) <.0001 
Gender                                          
Male 1,107   3.76  3,287   2.93 1.29 (1.21-1.39) 1.11 (1.02-1.20)   .011 
Female 3,179   7.54  9,753   6.06  1.25 (1.20-1.30) 1.11 (1.06-1.16) <.0001 
Agea        
<40    388   1.98  1,079   1.43 1.38 (1.23-1.55) 1.24 (1.07-1.44)   .005 
40-49    428   3.07  1,171   2.21 1.39 (1.24-1.55) 1.33 (1.15-1.51) <.0001 
50-59    636   4.74  1,945   3.84  1.24 (1.13-1.35) 1.16 (1.04-1.28)   .009 
60-69 1,052   7.87  3,021   5.96 1.33 (1.24-1.42) 1.15 (1.05-1.25)   .001 
70-79 1,128 13.36 3,629 11.14 1.21 (1.13-1.29) 1.02 (0.95-1.11)   .541 
≥80    654 23.41 2,195 20.30 1.15 (1.06-1.26) 1.00 (0.90-1.10)   .964 
                         a Age at the index date. 








Table 5. Overall incidence rates and hazard ratios (HR) for associations of site-specific fracture with exposure to asthma. 
Fracture 
location 
Asthma patients Non-asthma patients 





Number with a 
fracture 
Rate per 1000 
person-years 
Number with a 
fracture 
Rate per 1000 
person-years 
   
Forearm-Wrist 1,463 2.04  4,363 1.59 1.28 (1.20-1.35) 1.21 (1.13-1.30) <.0001 
Vertebra    685 0.96  1,845 0.67  1.42 (1.30-1.55) 1.19 (1.10-1.28) <.0001 
Hip    873 1.22 2,954 1.08  1.13 (1.05-1.22) 1.01 (0.92-1.08)    .905 
Humerus    598 0.83  1,842 0.67  1.24 (1.13-1.35) 1.05 (0.94-1.17)    .371 
Unspecifieda    667 0.93  2,036 0.74  1.26 (1.16-1.38) 1.06 (0.95-1.17)    .267 
            a Just a mention that it was a fragility fracture without specifying the exact fracture location. 







Fracture risk among asthma patients 
There were 17 233 (12.5%) patients with a median of 2 (IQR 1–4) and 87 675 (64%) distinct 
users with at least one OCS and ICS prescription per year of follow-up, respectively. The 
median prescriptions per year of follow-up were 2 (IQR: 1-4) for OCS and 5 (IQR: 2-7) for ICS. 
The fragility fracture risk increased from the 6th OCS course per year of follow-up (6-8 courses; 
aHR = 1.35, 95% CI 1.10-1.64), but only 45% had at least one BP prescription after the OCS 
initiation during the follow-up in this category (Supplementary Table E2). A larger risk due to 










Table 6. Risk of fragility fracture within asthma patients stratified by well-known risk factors. 










OCS prescriptions per person-year (n)  <.0001 
0        (120,890) 3,515   5.54   Reference   Reference  
1-2     (8,557)    326   7.62   1.37 (1.22-1.54)   0.97 (0.86-1.09)  
3-5     (5,795)    251   9.23   1.66 (1.46-1.89)   1.00 (0.88-1.14)  
6-8     (1,599)    105 14.28   2.60 (2.12-3.19)   1.35 (1.10-1.64)  
≥9      (1,282)      89 18.41   3.38 (2.71-4.21)   1.46 (1.16-1.83)  
ICS prescriptions per person-year (n)  <.0001 
0        (50,448) 1,766   7.05   Reference   Reference  
1-8     (79,692) 2,174   4.99   0.70 (0.66-0.75)   0.92 (0.85-1.01)  
9-13   (6,982)    252   9.43   1.34 (1.18-1.53)   0.95 (0.83-1.08)  
14-16 (812)      56 27.87   4.15 (3.17-5.41)   2.45 (1.93-3.20)  
≥17    (189)      20 67.26 10.01 (5.41-18.81)   6.15 (2.37-13.21)  
Gender     <.0001 
Male 1,107   3.76   Reference   Reference  
Female 3,179   7.54   2.00 (1.86-2.14)   2.13 (1.98-2.28)  
Age     <.0001 
≤40    388   1.98   Reference   Reference  
40-49    428   3.06   1.54 (1.34-1.77)   1.58 (1.38-1.81)  
50-59    636   4.74   2.34 (2.09-2.70)   2.46 (2.17-2.80)  
60-69 1,052   7.87   3.98 (3.55-4.47)   4.13 (3.66-4.65)  
70-79 1,128 13.36   6.88 (6.12-7.72)   6.72 (5.95-7.59)  
≥80    654 23.41 12.58 (11.09-14.27) 11.34 (9.91-12.98)  
Smoking     <.0001 
Never 1,736   5.29   Reference   Reference  
Former 1,517   7.04   1.34 (1.25-1.43)   1.09 (1.02-1.18)  
Current 1,033   6.19   1.17 (1.08-1.26)   1.35 (1.25-1.47)  
BMI (kg/𝒎𝟐)     <.0001 
Underweight (<18.5)    588 11.89   1.83 (1.51-2.21)   1.46 (1.19-1.79)  




Overweight (25 - 29.9) 1,296   5.80   0.92 (0.85-0.99)   0.83 (0.76-0.89)  
Obese (≥30) 1,145   5.08   0.82 (0.75-0.89)   0.71 (0.65-0.77)  
IMD      <.0001 
Least deprived    417   5.04    Reference   Reference  
-    479   5.93   1.18 (1.04-1.35)   1.11 (0.98-1.27)  
-    480   6.12   1.22 (1.07-1.39)   1.17 (1.03-1.33)  
-    394   5.28   1.05 (0.91-1.20)   1.02 (0.88-1.16)  
Most deprived    409   5.87   1.17 (1.02-1.34)   1.15 (1.02-1.31)  
Not known IMD 2,107   6.39   1.25 (1.13-1.39)   1.27 (1.14-1.41)  
         Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ICS, Inhaled Corticosteroids; IMD, Index of Multiple Deprivation; OCS, Oral corticosteroids. 







Overall, this study shown that asthma is associated with an increased risk of osteoporosis and 
FF. This association was stronger in the younger age groups. Among patients with asthma, a 
single OCS course raised the osteoporosis risk, and greater use of ICS increased the risk of 
both bone diseases.  
To the best of our knowledge, this is the largest study reporting the incidence and risk of 
osteoporosis and FF in asthma using a primary care database. Other strength is the 
population-based setting that means the findings are generalizable to the wider population. 
We captured osteoporosis and fragility fracture diagnoses for the general population of  
asthma and not just for a specific one such as people with severe asthma. We were able to 
adjust for a wide range of potentially confounding factors. Our results were also robust to 
sensitivity analyses. 
The data use from primary care databases has some limitations. Firstly, there may be 
misclassification of asthma, osteoporosis, and FF diagnoses, as we were reliant on how 
accurately general practitioners record these conditions. However, these diagnoses have 
been previously validated in the database demonstrating a positive predictive value around 
90%; therefore, the existence of any diagnosis misclassification in our study should be very 
unlikely (27,28). In addition, most fractures are painful and medical treatment would be sought 
for it and it be recorded, however, vertebral fractures or osteoporosis often do not come to 
clinical attention, and people might not be aware of these conditions (29); this may result in 
the underestimation of their coding and as a result of their risk. Nevertheless, we do not think 
this underestimation would be different in people with asthma than people who do not have 
asthma. As in all health care datasets, our prescriptions were based on issued prescriptions 
without knowing whether or not they were dispensed. 
The absolute incidence rate of each FF site in our general population is in accordance with 




to population statistics in the UK (10.8 vs 10.3 per 10,000 person-years) (31). The observed 
rate is consistent with the limited published studies examining the osteoporosis and fracture 
risk in asthma. However, these studies were small (e.g. 105 patients vs 133 controls), lacked 
data on important confounders such as BMI, socioeconomic status, or focused on specific 
asthma group providing a little information about the risk in asthma (20,22,32). Sweeney et al. 
found a higher risk of osteoporosis and fracture compared to our study which probably reflects 
the more severe asthma population (20). We found greater risk of spine and forearm fractures 
in accordance with reports shown a lower BMD at these sites in patients with asthma (7,18,33), 
but not a significant risk of hip fractures in agreement with a meta-analysis (34) which did not 
find a reduced BMD at femur/hip between patients with asthma and controls.  
Our study found the effect of asthma on osteoporosis is stronger in younger people and males 
and on FF in younger people. This observation may be due to other factors such as previous 
fractures, low oestrogen level, comorbidities, and other medications which have a bigger 
impact on the risk of osteoporosis and fragility fracture and are more likely in older people or 
women. Therefore, at younger ages and in men the main risk factor for osteoporosis will be 
steroids, hence the stronger relationship. Lastly, men and younger generally receive 
osteoporosis treatment less frequently than women and older people (35), as this was 
demonstrated in our findings.  Knowledge that the effect of asthma on osteoporosis and FF is 
stronger in younger people is crucial in daily asthma practice in terms of the management of 
corticosteroid therapy minimising the side effects in subpopulation being at higher risk. 
Furthermore, as the effect of asthma on osteoporosis is stronger in males a high awareness 
is recommended not only in female but in male patients with asthma 
Previous studies have reported an increase in fracture risk in relation to daily and cumulative 
OCS use, and our study shows that even one prescription per year increases the risk 
(13,20,36). Concerns about the negative impact of ICS on bones are recognised with long-
term use (≥0.7mg/day) (14), with our findings confirming the negative effects on bone of ICS 




and use the lowest dose possible to maintain asthma control (37). Although there is clear 
guidance on OCS and bisphosphonate therapy in the general population, there is no current 
recommendation for BP therapy for ICS users, despite evidence supporting fractures-related 
to ICS (14,38).  
Current UK guidelines on asthma do not cover the management of these bone comorbidities 
appropriately due to the very few studies specific to asthma. Specifically, the BTS/SIGN 
guideline on asthma management cover specific co-morbidities including osteoporosis, but 
not specific bone protection guidance is given (2), and the NICE asthma guideline does not 
mention osteoporosis at all (39). Our results suggest that osteoporosis and FF should be 
addressed explicitly in future guideline updates. 
Conclusion 
Patients with asthma have an increased osteoporosis and FF risk compared to the general 
population, in particular vertebral and humerus fractures. An increased awareness of these 
bone disease comorbidities in asthma, particularly in the younger population, is needed. 
Reviewing corticosteroid dose and using the lowest dose possible minimising the risk of these 
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